PubMed Health⌕ Search

PubMed · 12529225

Practicing a Structured Continuous Key-Pressing Task: Motor Chunking or Rhythm Consolidation?

Abstract

An experiment is reported on the effects of extensive practice in a task in which subjects (N = 36) pressed a succession of nine keys with nine separate fingers, each key press in response to a corresponding stimulus. The order of the key presses remained constant over practice. Key-pressing cycles followed each other without interruption. A stimulus was usually presented immediately upon depressing the previous key, but in the structured conditions a stimulus was preceded at either two (the 45 group) or three (the 333 group) positions by a 750-ms response-stimulus interval (RSI). This partitioned the sequence into three response groups for subjects in the 333 condition and into two response groups for subjects in the 45 condition. On occasion, all subjects performed in the unstructured condition, in which RSls were zero. Interkey times in this condition clearly reflected the position of the 750-ms RSls in the structured conditions. This suggests that motor chunks developed in the structured conditions were also used in the unstructured condition. Rhythm-based control, as proposed by Summers (1975), was rejected as an explanation for this effect because group-start-within-group ratios exceeded 2:1 and because the theory of rhythm-based control could not predict intervals in the unstructured 45 condition. Unstructured within-group intervals were slower than structured within-group intervals, which effect was more pronounced in the 333 than in the 45 condition. Also, the initial element of the unstructured four-key group was faster than the initial element of the unstructured three-key group. These and other findings (a) accord with the notion that in unstructured sequences preparing a forthcoming response group concurs with the execution of the preceding group and (b) suggest that shorter groups are more slowed by concurrent preparation for the forthcoming group than are longer groups.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

W. B. Verwey, Y. Dronkert. 1996. Practicing a Structured Continuous Key-Pressing Task: Motor Chunking or Rhythm Consolidation?. https://doi.org/10.1080/00222895.1996.9941735

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Effectiveness of high-dose versus standard-dose influenza vaccines against hospitalisation according to frailty risk: a prespecified analysis of the randomised trial DANFLU-2.

BACKGROUND: Frailty is a major risk factor for influenza-related complications and can influence vaccine effectiveness. We aimed to assess the relative vaccine effectiveness (rVE) of high-dose (HD-IIV) versus standard-dose inactivated influenza vaccine (SD-IIV) in older adults aged 65 years or older according to frailty risk. METHODS: This study was a prespecified analysis of DANFLU-2, an open-label, individually randomised trial, conducted in Denmark during three consecutive influenza seasons (2022-23, 2023-24, and 2024-25). Adults aged 65 years or older were randomised (1:1) to the HD-IIV or SD-IIV group. The primary endpoint was hospitalisation for influenza or pneumonia. Frailty was defined according to the validated Hospital Frailty Risk Score (HFRS) based on ICD-10 codes within 10 years before randomisation. Participants were stratified into three HFRS categories, namely low (<5 points), intermediate (5-15 points), and high (>15 points) frailty risk. The rVE of HD-IIV versus SD-IIV against the primary endpoint was assessed across prespecified HFRS categories and treating HFRS as a continuous variable. Pearson's chi-square test was used to compare safety events across frailty risk groups and randomisation groups. FINDINGS: Among 332&#x2009;438 randomised participants (mean age 73&#xb7;7 years [SD 5&#xb7;8]; 161&#x2009;538 [48&#xb7;6%] were female), 276&#x2009;173 (83&#xb7;1%) had low frailty risk, 52&#x2009;395 (15&#xb7;8%) had intermediate frailty risk, and 3861 (1&#xb7;2%) had high frailty risk. The primary endpoint of hospitalisation for influenza or pneumonia occurred in 1424 (0&#xb7;5%) of 276&#x2009;173 participants with low frailty risk, 761 (1&#xb7;5%) of 52&#x2009;395 with intermediate frailty risk, and 163 (4&#xb7;2%) of 3861 with high frailty risk (relative risk [RR] for intermediate vs low frailty risk 2&#xb7;8 [95% CI 2&#xb7;6-3&#xb7;1]; RR for high vs low frailty risk 8&#xb7;2 [7&#xb7;0-9&#xb7;6]). HFRS as a continuous variable significantly modified the effect of HD-IIV versus SD-IIV against the primary endpoint with higher rVE estimates with increasing HFRS (pinteraction=0&#xb7;020). The rVE was 0&#xb7;2% (95% CI -10&#xb7;8 to 10&#xb7;2) among those with low frailty risk, 13&#xb7;1% (-0&#xb7;4 to 24&#xb7;8) among those with intermediate frailty risk, and 19&#xb7;9% (-10&#xb7;3 to 42&#xb7;1) among those with high frailty risk. No significant interaction was observed when HFRS was assessed according to the prespecified categorical frailty groups (pinteraction=0&#xb7;17). The proportion of participants with at least one serious adverse event increased across frailty risk groups (13&#x2009;366 [4&#xb7;8%] of 275&#x2009;795 for low frailty risk, 5475 [10&#xb7;5%] of 52&#x2009;315 for intermediate frailty risk, and 777 [20&#xb7;2%] of 3850 for high frailty risk; p<0&#xb7;0001), with similar proportions of serious adverse events in the HD-IIV and SD-IIV groups for each frailty risk group. INTERPRETATION: Among adults aged 65 years or older in Denmark, frailty risk might modify the effects of HD-IIV versus SD-IIV against hospitalisation for influenza or pneumonia, with higher rVE estimates with increasing frailty risk. These findings might support considering high-dose influenza vaccines for frail older adults. However, effect modification was not evident when frailty was assessed using prespecified categorical subgroups, and subgroup-specific estimates were imprecise, with 95% CIs crossing the null. These results should be considered exploratory, warranting further investigation. FUNDING: The DANFLU-2 trial was funded by Sanofi.

Journal Article↗